T
Tessera Therapeutics
A new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source
News
Open roles
Tessera Therapeutics in the Cambridge ecosystem
The Tessera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later16 investors entered at this stage
- RPRegeneron Pharmaceuticals
- AFAlaska Permanent Fund
- MPMarch Capital Partners
- AVArtis Ventures
- AAAbu Dhabi Investment Authority
- AVAltitude Life Science Ventures
Cormorant Asset Management- LFLongevity Vision Fund
SoftBank- UCUniversity of California
- BEBerkeley
T. Rowe Price- SFSALT Fund
Qatar Investment Authority- HIHanwha Impact
Flagship Pioneering
Source: Dealroom Talent Intelligence.
Alumni founders
Former Tessera Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
LBLiberate BioEst. 2022
Michael J MitchellUnited States
GBGenerate BiomedicinesEst. 2020
Molly GibsonUnited States
QTQuotient TherapeuticsEst. 2022
Jacob Rubens.United Kingdom
MHMontai HealthEst. 2022
Noubar AfeyanUnited StatesPatents
9 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Tessera Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


